Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 180,769 shares changed hands during mid-day trading, an increase of 2% from the previous session's volume of 176,763 shares.The stock last traded at $9.00 and had previously closed at $8.83.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on ABVX. Citigroup reissued a "market outperform" rating on shares of Abivax in a research report on Friday. JMP Securities set a $33.00 target price on shares of Abivax in a report on Friday. Finally, Morgan Stanley restated an "equal weight" rating and set a $12.00 price target on shares of Abivax in a research report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Abivax currently has an average rating of "Buy" and a consensus price target of $31.00.
Read Our Latest Stock Report on ABVX
Abivax Trading Down 3.8%
The stock has a 50 day moving average price of $7.14 and a 200-day moving average price of $6.80. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.25 and a quick ratio of 1.25.
Hedge Funds Weigh In On Abivax
Hedge funds and other institutional investors have recently modified their holdings of the business. Two Sigma Investments LP purchased a new position in Abivax in the 4th quarter worth approximately $144,000. JPMorgan Chase & Co. acquired a new stake in shares of Abivax in the fourth quarter valued at approximately $5,336,000. GAMMA Investing LLC boosted its stake in Abivax by 373.6% during the first quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock worth $118,000 after buying an additional 14,855 shares during the last quarter. Guggenheim Capital LLC purchased a new stake in Abivax in the 4th quarter valued at $92,000. Finally, Millennium Management LLC increased its stake in shares of Abivax by 44.2% in the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company's stock worth $6,816,000 after acquiring an additional 285,542 shares during the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.
About Abivax
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Recommended Stories
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
